Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFM-DACORAL-DLI
2024-515353-24-00Phase 2Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inqovi in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML), sponsored by Groupe Français des Myélodysplasies. Primary endpoint: Disease-free survival at 1 year post transplant. Started Oct 2024; status: completed.
02
Drugs
inqovi
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-515353-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515353-24-00.